185 related articles for article (PubMed ID: 36822438)
1. The role of m6A-mediated PD-1/PD-L1 in antitumor immunity.
Liu L; Liang L; Li H; Shao W; Yang C; Lin F; Liu J; Zhang J
Biochem Pharmacol; 2023 Apr; 210():115460. PubMed ID: 36822438
[TBL] [Abstract][Full Text] [Related]
2. N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.
Luo P; Li S; Long X
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188873. PubMed ID: 36842764
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
4. The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity.
Yu W; Lin J; Yu T; Lou J; Qian C; Xu A; Liu B; Tao H; Jin L
Immunol Cell Biol; 2023 Mar; 101(3):204-215. PubMed ID: 36630591
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
6. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.
Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
Front Immunol; 2022; 13():845193. PubMed ID: 35154166
[TBL] [Abstract][Full Text] [Related]
7. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
8. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():765723. PubMed ID: 35003079
[TBL] [Abstract][Full Text] [Related]
9. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
12. m
Wang A; Sun Y; Wang X; Yan Z; Wang D; Zeng L; Lu Q
Aging (Albany NY); 2023 Aug; 15(16):8444-8457. PubMed ID: 37647025
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Xiong W; Gao Y; Wei W; Zhang J
Trends Cancer; 2021 Sep; 7(9):837-846. PubMed ID: 33903073
[TBL] [Abstract][Full Text] [Related]
15. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
16. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
Wang G; Zeng D; Sweren E; Miao Y; Chen R; Chen J; Wang J; Liao W; Hu Z; Kang S; Garza LA
J Invest Dermatol; 2023 Aug; 143(8):1579-1590.e5. PubMed ID: 36842525
[TBL] [Abstract][Full Text] [Related]
19. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
20. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]